Characterization of side population cells in human malignant mesothelioma cell lines

被引：34

作者：

Kai, Kiyonori ^{[1
,3
]}

D'Costa, Susan ^{[1
]}

Yoon, Byung-Il ^{[1
,4
]}

Brody, Arnold R. ^{[2
]}

Sills, Robert C. ^{[5
]}

Kim, Yongbaek ^{[1
]}

机构：

[1] N Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC 27606 USA

[2] N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA

[3] Daiichi Sankyo Co Ltd, Med Safety Res Labs, Shinagawa Ku, Tokyo 1408710, Japan

[4] Kangwon Natl Univ, Sch Vet Med, Chunchon, South Korea

[5] NIEHS, Cellular & Mol Pathol Branch, Res Triangle Pk, NC 27709 USA

来源：

LUNG CANCER | 2010年 / 70卷 / 02期

关键词：

Mesothelioma; Side population; Cancer stem cell; Hoechst; 33342; Tumorigenicity; Flow cytometry; CANCER STEM-CELLS; IN-VIVO; RESISTANCE; IDENTIFICATION; PATHWAY; TUMORS; GENE;

D O I：

10.1016/j.lungcan.2010.04.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Side population (SP) assay composed of Hoechst 33342 staining and subsequent flow cytometric analysis has been widely utilized for characterizing putative cancer stem cells (CSCs) in various human malignancies. The present study was designed to evaluate the SP assay as a research tool for mesothelial CSCs. A distinct fraction of SP cells was identified in various human malignant mesothelioma (HMM) cell lines, ranging from 0.05 to 1.32%. The sorted mesothelial SP cells exhibited enhanced proliferation potentials and higher expression of stem-cell genes, compared to non-SP (NSP) cells. Cisplatin treatment increased percentage of SP cells in the HMM cell lines. However, tumorigenic potential of SP cells in immunodeficient mice was similar to that of the NSP cells. These data indicated that SP assay may not be appropriate for enriching putative CSCs in HMM cell lines, and thus warrants the development of a novel tool for mesothelial CSC study. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：146 / 151

页数：6

共 23 条

[1] Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M
Wicha, MS
Benito-Hernandez, A
Morrison, SJ
Clarke, MF
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) : 3983 - 3988
[2] Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940
[3] Opinion - The origin of the cancer stem cell: current controversies and new insights
Bjerkvig, R
Tysnes, BB
Aboody, KS
Najbauer, J
Terzis, AJA
[J]. NATURE REVIEWS CANCER, 2005, 5 (11) : 899 - 904
[4] The pathogenesis of mesothelioma
Carbone, M
Kratzke, RA
Testa, JR
[J]. SEMINARS IN ONCOLOGY, 2002, 29 (01) : 2 - 17
[5] Tumour stem cells and drug resistance
Dean, M
Fojo, T
Bates, S
[J]. NATURE REVIEWS CANCER, 2005, 5 (04) : 275 - 284
[6] Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo
Goodell, MA
Brose, K
Paradis, G
Conner, AS
Mulligan, RC
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) : 1797 - 1806
[7] Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells
Ho, Maria M.
Ng, Alvin V.
Lam, Stephen
Hung, Jaclyn Y.
[J]. CANCER RESEARCH, 2007, 67 (10) : 4827 - 4833
[8] Tumor growth need not be driven by rare cancer stem cells
Kelly, Priscilla N.
Dakic, Aleksandar
Adams, Jerry M.
Nutt, Stephen L.
Strasser, Andreas
[J]. SCIENCE, 2007, 317 (5836) : 337 - 337
[9] Kim M, 2002, CLIN CANCER RES, V8, P22
[10] Major carcinogenic pathways identified by gene expression analysis of peritoneal mesotheliomas following chemical treatment in F344 rats
Kim, Yongbaek
Ton, Thai-Vu
DeAngelo, Anthony B.
Morgan, Kevin
Devereux, Theodora R.
Anna, Colleen
Collins, Jennifer B.
Paules, Richard S.
Crosby, Lynn M.
Sills, Robert C.
[J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2006, 214 (02) : 144 - 151

← 1 2 3 →